Antiparkinsonian and neuroprotective effects of modafinil in the mptp-treated common marmoset

Experimental Brain Research

Volumn 133, Issue 2, 2000, Pages 178-188

  Jenner, P ^a   Zeng, B Y ^a   Smith, L A ^a   Pearce, R K B ^a   Tel, B ^a   Chancharme, L ^b   Moachon, G ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b Centre de Recherches   (France)

Author keywords

Modafinil; MPTP treatment; Primates

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; MODAFINIL; PSYCHOSTIMULANT AGENT; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN PROTECTION; CELL DEATH; CONTROLLED STUDY; FEMALE; MALE; MARMOSET; MOTOR ACTIVITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SUBSTANTIA NIGRA; TIME;

EID: 0033939751     PISSN: 00144819     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002210000370     Document Type: Article

References (56)

1. Abercrombie M (1946) Estimation of the nuclear population from microtome sections. Anat Res 94:239-247
2. Akaoka H, Roussel B, Lin J, Chouvet G, Jouvet M (1991) Effect of modafinil on the rat catecholaminergic neuron activity. Neurosci Lett 123:20-22
3. Albin RL, Young AB, Penney JB (1989) The functional anatomy of basal ganglia disorders. Trends Neurosci 12:366-375
4. Bastuji H, Jouvet M (1988) Successful treatment of idiopathic hypersomnia and narcolepsy with modafinil. Prog Neuropsychopharmacol Biol Psychiatry 12:695-700
5. Beal MF (1995) Aging, energy, and oxidative stress in neurodegenerative disease. Ann Neurol 38:357-366
6. Birkmayer W, Knoll J, Riederer P (1985) Improvement of life expectancy due to L-deprenyl addition to Madopar treatment in Parkinson's disease: a long-term study. J Neural Transm 64: 113-127
7. Bradley P, Engel G, Feniuk W (1986) Proposal for the classification and nomenclature of functional receptors for 5-hydroxytrptamine. Neuropharmacology 25:563-576
8. Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ (1983) A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci USA 80:4546-4550
9. Crossman AR (1990) A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment. Mov Disord 5:100-108
10. DeLong MR (1990) Primate model of movement disorders of basal ganglia origin. Trends Neurosci 13:281-285
11. Di Monte DA (1991) Mitochondrial DNA and Parkinson's disease. Neurology 41:38-42
12. Ferraro L, Tanganelli S, O'Connor W, Antoneli T, Rambert F, Fuxe K (1996a) The vigilance promoting drug modafinil increases dopamine release in the rat nucleus accumbens via the involvement of a local GABAergic mechanism. Eur J Pharmacol 306:33-39
13. Ferraro L, Tanganelli S, O'Connor W, Antoneli T, Rambert F, Fuxe K (1996b) The vigilance promoting drug modafinil decrease GABA release in the medial preoptic area and in the posterior hypothalamus of the awake rat: possible involvement of the serotonergic 5-HT3 receptor. Neurosci Lett 220:5-8
14. Ferraro L, Antonelli T, O'Connor WT, Tanganelli S, Rambert FA, Fuxe K (1997a) Modafinil: an antinarcoleptic drug with a different neurochemical profile to D-amphetamine and dopamine uptake blockers. Biol Psychiatry 42:1181-1183
15. Ferraro L, Antonelli T, O'Connor WT, Tanganelli S, Rambert FA, Fuxe K (1997b) The antinarcoleptic drug modafinil increases glutamate release in thalamic areas and hippocampus. Neuroreport 8:2883-2887
16. Fuxe K, Janson AM, Rosen L (1992) Evidence for a protective action of the vigilance promoting drug modafinil on the MPTP-induced degeneration of the nigrostriatal dopamine neurons in the black mouse: an immunocytochemical and biochemical analysis. Exp Brain Res 88:117-130
17. Fuxe K, Rambert FA, Ferraro L (1996) Preclinical studies with modafinil. Evidence for vigilance enhancement and neuroprotection. Drugs of Today 32:313-326
18. Gash DM, Zhang Z, Ovadia A, Cass WA, Yi A, Simmerman L, Russell D, Martin D, Lapchak PA, Collins F, Hoffer BJ, Gerhardt GA (1996) Functional recovery in parkinsonian monkeys treated with GDNF. Nature 380:252-255
19. Heikkila RE, Hess A, Duvoisin RC (1984) Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydro-pyridine in mice. Science 224:1451-1453
20. Herrero MT, Augood AJ, Hirsch EC, Javor-Agid F, Luquin MR, Agid Y, Obeso JA, Emson PC (1995) Effects of L-DOPA on preproenkephalin and preprotachykinin gene expression in the MPTP-treated monkey striatum. Neuroscience 68:1189-1198
21. Hirsch EC (1993) Does oxidative stress participate in nerve cell death in Parkinson's disease? Eur Neurol [Suppl] 33:52-59
22. Janson AM, Fuxe K, Goldstein M (1994) The MPTP model of Parkinson's disease in the mouse. Modafinil - a new potential neuroprotective agent. In: Fuxe K, Agnati L, Bjelke B (eds) Trophic regulation of the basal ganglia. Focus on dopamine neurones. Pergamon Press, Oxford, pp 409-423
23. 3H]-mazindol autoradiography. J Neurosci 5:1513-1521
24. Jenner P, Olanow CW (1996) Pathological evidence for oxidative stress in Parkinson's disease and related degenerative disease. In: Olanow CW, Jenner P, Youdim M (eds) Neurodegeneration and neuroprotection in Parkinson's disease, chapter 2. Academic Press, New York, pp 24-45
25. Jenner P, Rose S, Boyce S, Marsden CD (1986) Induction of parkinsonism in the common marmoset by administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. In: Fahn S, Marsden CD, Jenner P (eds) Recent developments in Parkinson's disease. Raven Press, New York, pp 23-28
26. Jolkkonen J, Jenner P, Marsden CD (1995) L-DOPA reverses altered gene expression of substance P but not enkephalin in the caudate-putamen of common marmosets treated with MPTP. Brain Res Mol Brain Res 32:297-307
27. Konigsmark BW (1970) Methods for the counting of neurones. In: Nauta WJH, Ebbesson SOE (eds) Contemporary research methods in neuroanatomy. Springer, Berlin Heidelberg New York, pp 215-340
28. Lagarde D, Anton G (1990) Comparative study of stimulant effects of D-amphetamine sulfate and modafinil, an original psychostimulant. Eur J Pharmacol 183:1476
29. Langston JW, Ballard P, Tetrud JW, Irwin I (1983) Chronic parkinsonism in humans due to a product of mepridine-analog synthesis. Science 219:979-980
30. Langston JW, Forno LS, Robert CS, Irwin I (1986) Selective nigral toxicity after systemic administation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the squirrel monkey. Brain Res 292:390-394
31. Löschmann PA, Smith LA, Lange KW, Jähnig P, Jenner P, Marsden CD (1992) Motor activity following the administration of selective D-1 and D-2 dopaminergic drugs to MPTP-treated common marmosets. Psychopharmacology 109:49-56
32. Melamed E, Rosenthal J, Globus M, Cohen O, Uzzan A (1985) Suppression of MPTP-induced dopaminergic neurotoxicity in mice by nomifensine and L-DOPA. Brain Res 342:401-404
33. Mignot E, Nishino S, Guilleminault C, Dement W (1994) Modafinil binds to the dopamine uptake carrier site with low affinity. Sleep 17:436-437
34. Miyoshi Y, Zhang Z, Ovadia A (1997) Glial cell line-derived neurotrophic factor-levodopa interactions and reduction of side effects in Parkinsonian monkeys. Ann Neurol 42:208-214
35. Morissette M, Coulet M, Soghomonian JJ, Blanchet PJ, Calon F, Bedard PJ, Di Paolo T (1997) Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D-2 agonist U91356A in continuous or intermittent mode of administration: comparison with L-DOPA therapy. Brain Res Mol Brain Res 49:55-62
36. Nisbet AP, Foster OJE, Kingsbury A, Eve DJ, Daniel SE, Marsden CD, Lees AJ (1995) Preproenkephalin and preprotachykinin messenger RNA expression in normal human basal ganglia and in Parkinson's disease. Neuroscience 66:361-376
37. Olanow CW (1996) Deprenyl in the treatment of Parkinson's disease - clinical effects and speculations on mechanism of action. J Neural Transm 48:75-84
38. The Parkinson Study Group (1993) Effect of tocopherol and deprenyl on the progression of disability in early Parinson's disease. N Engl J Med 328:176-183
39. Pearce RKB, Banerji T, Scheel-Kruger J, Jenner P (1995) The dopamine reuptake blocker NS 2214 increases locomotor activity, but does not produce dyskinesia in MPTP-treated common marmosets. Br J Pharmacol [Suppl] 116:304
40. Pileblad E, Carlsson A (1985) Catecholamine-uptake inhibitors prevent the neurotoxicity of 1-methyl-4 phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mouse brain. Neuropharmacology 24:689-692
41. Rambert FA, Pessonnier J, Duteil J (1990) Modafinil-amphetamine- and methylphenidate-induced hyperactivities in mice involve different mechanisms. Eur J Pharmacol 183:455-459
42. Ramsay RR, Dadgar J, Trevor A, Singer TP (1986) Energy-driven uptake of N-methyl-4-phenylpyri-dine by brain mitochondria mediates the neurotoxicity of MPTP. Life Sci 39:581-588
43. Schultz W, Scarnati E, Sundstrom E, Tsutsumi T, Jonsson G (1986) The catecholamine uptake blocker nomifensine protects against MPTP-induced parkinsonism in monkeys. Exp Brain Res 63:216-220
44. Simon P, Hemet C, Ramasamy C, Costentin J (1995) Non-amphetamine mechanism of stimulant locomotor effect of modafinil in mice. Eur Neuropsychopharmacol 5:509-514
45. Smith LA, Gordin A, Jenner P, Marsden CD (1997) Entacapone enhances levodopa-induced reversal of motor disability in MPTP-treated common marmosets. Mov Disord 12:935-945
46. Soghomonian JJ, Laprade N (1997) Glutamate decarboxylase (GAD67 and GAD65) gene expressioon is increased in a subpopulation of neurones in the putamen of parkinsonian monkeys. Synapse 27:122-132
47. Starr MS (1995) Antiparkinsonian actions of glutamate antagonists - alone and with L-DOPA: a review of evidence and suggestions for possible mechanisms. J Neural Transm 10:141-185
48. Stephan H, Baron G, Schwerdtfeger WK (1980) The brain of the common marmoset: a stereotactic atlas. Springer, Berlin Heidelberg New York
49. Sundstrom E, Jonsson G (1986) Differential time course of protection by monoamine oxidase inhibition and uptake inhibition against MPTP neurotoxicity on central catecholamine neurons in mice. Eur J Pharmacol 122:275-278
50. Sundstrom E, Stromberg I, Tsutsumi T, Olson L, Jonsson G (1987) Studies on the effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in C57 BL/6 mice. Comparison with three other strains of mice. Brain Res 405:26-38
51. Tanganelli S, Fuxe K, Ferraro L, Janson AM, Bianchi C (1992) Inhibitory effects of the psychoactive drug modafinil on r-aminobutyric acid outflow from the cerebral cortex of the awake freely moving guinea-pig. Possible involment of 5-hydroxytryptamine mechanisms. Naunyn Schmiedebergs Arch Pharmacol 345:461-465
52. Tanganelli S, Perez de la Mora M, Ferraro L (1995) Modafinil and cortical r-aminobutyric acid outflow modulation by 5-hydroxytryptamine neurotoxins. Eur J Pharmacol 273:63-71
53. Ueki A, Rosen L, Andbjer B, Finnnman U-B, Altamini U, Janson AM, Goldsein M, Agnati LF, Fuex K (1993a) The vigilance-promoting drug modafinil counteracts the reduction of tyrosine hydroxylase immunoreactive and of dopamine stores in nigrostriatal dopamine neurones in the male rat after a partial transection of the dopamine pathway. Exp Brain Res 93:259-270
54. Ueki A, Rosen L, Andbjer B, Agnati LF, Hallstrom A, Goiny M, Tanganelli S, Ungerstedt U, Fuex K (1993b) Evidence for a preventive action of the vigilance-promoting drug modafinil against striatal ischemic injury induced by endothelin-1 in the rat. Exp Brain Res 96:89-99
55. Zeng BY, Jenner P, Marsden CD (1996) Altered motor function and graft survival produced by basic fibroblast growth factor in rats with 6-OHDA lesions and fetal ventral mesencephalic grafts are associated with glial proliferation. Exp Neurol 139:214-226
56. Zeng BY, Tel BC, Pearce RKB, Smith LA, Chancharme L, Moachon G, Rose S, Jenner P, Marsden CD (1997) Neuroprotective effect of modafinil against MPTP toxicity in MPTP-treated common marmosets. Br J Pharmacol 122:44